# Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

> **NCT00539253** · NA · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 45 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** gadobenate dimeglumine (MultiHance)

## Key facts

- **NCT ID:** NCT00539253
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2013-03
- **Final completion:** 2013-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00539253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00539253, "Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00539253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*